These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16772753)

  • 1. Are cholinesterase inhibitors more than symptomatic treatments for Alzheimer disease?
    Relkin N
    Alzheimer Dis Assoc Disord; 2006; 20(2 Suppl 1):S2. PubMed ID: 16772753
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease.
    Nordberg A
    Alzheimer Dis Assoc Disord; 2006; 20(2 Suppl 1):S12-8. PubMed ID: 16772751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What constitutes clinical evidence for neuroprotection in Alzheimer disease: support for the cholinesterase inhibitors?
    Mori E; Hashimoto M; Krishnan KR; Doraiswamy PM
    Alzheimer Dis Assoc Disord; 2006; 20(2 Suppl 1):S19-26. PubMed ID: 16772752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Alzheimer's disease.
    Mayeux R; Sano M
    N Engl J Med; 1999 Nov; 341(22):1670-9. PubMed ID: 10572156
    [No Abstract]   [Full Text] [Related]  

  • 6. [The treatment of Alzheimer's disease].
    Ankri J
    Rev Neurol (Paris); 2003 Sep; 159(8-9):819-24. PubMed ID: 13679729
    [No Abstract]   [Full Text] [Related]  

  • 7. Alzheimer's disease: clinical evaluation and disease management--update.
    Richter RW
    J Okla State Med Assoc; 2004 Dec; 97(12):546-54; quiz 555-6. PubMed ID: 15732886
    [No Abstract]   [Full Text] [Related]  

  • 8. [Rivastigmine solution prescribing habits in patients with Alzheimer-type dementia in Spain (RIVASOL study)].
    González-Gutiérrez JL; Gobartt AL;
    Rev Neurol; 2007 Jun 16-30; 44(12):705-10. PubMed ID: 17583861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galantamine improves gait performance in patients with Alzheimer's disease.
    Assal F; Allali G; Kressig RW; Herrmann FR; Beauchet O
    J Am Geriatr Soc; 2008 May; 56(5):946-7. PubMed ID: 18454755
    [No Abstract]   [Full Text] [Related]  

  • 10. Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease.
    Zhang HY; Tang XC
    Trends Pharmacol Sci; 2006 Dec; 27(12):619-25. PubMed ID: 17056129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacological correction of Alzheimer's disease (review of the literature)].
    Groppa SA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1991; 91(9):110-6. PubMed ID: 1686127
    [No Abstract]   [Full Text] [Related]  

  • 12. [Cholinesterase inhibitors in Alzheimer disease: preliminary recommendations for the practice].
    Schölzel-Dorenbos CJ; Jellesma-Eggenkamp MJ
    Ned Tijdschr Geneeskd; 1999 Jan; 143(2):122-3. PubMed ID: 10086120
    [No Abstract]   [Full Text] [Related]  

  • 13. Realizing early treatment benefits in dementia.
    Gauthier SG
    Eur J Neurol; 2005 Oct; 12 Suppl 3():1-2. PubMed ID: 16144530
    [No Abstract]   [Full Text] [Related]  

  • 14. FPIN's clinical inquiries. Monitoring therapy for patients with Alzheimer's disease.
    Raetz J; v d Luft E
    Am Fam Physician; 2007 Jun; 75(11):1703-4. PubMed ID: 17575663
    [No Abstract]   [Full Text] [Related]  

  • 15. Cholinesterase inhibitors in vascular cognitive impairment.
    Massoud F
    Can J Neurol Sci; 2013 Jul; 40(4):446-7. PubMed ID: 23786722
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of rivastigmine on cognitive function in patients with traumatic brain injury.
    Noble JM; Hauser WA
    Neurology; 2007 May; 68(20):1749; author reply 1750. PubMed ID: 17502565
    [No Abstract]   [Full Text] [Related]  

  • 17. Realistic expectations for treatment success in Alzheimer's disease.
    Geldmacher DS; Frolich L; Doody RS; Erkinjuntti T; Vellas B; Jones RW; Banerjee S; Lin P; Sano M
    J Nutr Health Aging; 2006; 10(5):417-29. PubMed ID: 17066215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New developments in the treatment of Alzheimer's disease.
    J Clin Psychiatry; 2009 Feb; 70(2):281-90. PubMed ID: 19265644
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of degenerative dementia disorders--who should be treated?].
    Hasselbalch SG; Kampmann JP
    Ugeskr Laeger; 2009 Mar; 171(10):802-5. PubMed ID: 19265606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cholinesterase inhibitors in Alzheimer disease; preliminary recommendations for the practice].
    Van Zwieten-Boot BJ; Lekkerkerker JF
    Ned Tijdschr Geneeskd; 1998 Nov; 142(48):2644-5; author reply 2645-6. PubMed ID: 10028368
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.